Slack JA - Search Results

1

Phase I study of intravenous 4-hydroxyanisole.

Rustin GJ, Stratford MR, Lamont A, Bleehen N, Philip PA, Howells N, Watfa RR, Slack JA. Rustin GJ, et al. Among authors: slack ja. Eur J Cancer. 1992;28A(8-9):1362-4. doi: 10.1016/0959-8049(92)90520-c. Eur J Cancer. 1992. PMID: 1515252 Clinical Trial.

2

Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).

Newlands ES, Blackledge GR, Slack JA, Rustin GJ, Smith DB, Stuart NS, Quarterman CP, Hoffman R, Stevens MF, Brampton MH, et al. Newlands ES, et al. Among authors: slack ja. Br J Cancer. 1992 Feb;65(2):287-91. doi: 10.1038/bjc.1992.57. Br J Cancer. 1992. PMID: 1739631 Free PMC article. Clinical Trial.

3

A phase I study of meta-azidopyrimethamine ethanesulphonate (MZPES)--a new dihydrofolate reductase inhibitor.

Stuart NS, Crawford SM, Blackledge GR, Newlands ES, Slack J, Hoffman R, Stevens MF. Stuart NS, et al. Cancer Chemother Pharmacol. 1989;23(5):308-10. doi: 10.1007/BF00292409. Cancer Chemother Pharmacol. 1989. PMID: 2706736

4

Phase I clinical trial of mitozolomide.

Newlands ES, Blackledge G, Slack JA, Goddard C, Brindley CJ, Holden L, Stevens MF. Newlands ES, et al. Among authors: slack ja. Cancer Treat Rep. 1985 Jul-Aug;69(7-8):801-5. Cancer Treat Rep. 1985. PMID: 4016790

5

EORTC/CRC/NCI guidelines for the formulation of investigational cytotoxic drugs.

Davignon JP, Slack JA, Beijnen JH, Vezin WR, Schoemaker TJ. Davignon JP, et al. Among authors: slack ja. Eur J Cancer Clin Oncol. 1988 Sep;24(9):1535-8. doi: 10.1016/0277-5379(88)90349-5. Eur J Cancer Clin Oncol. 1988. PMID: 3181274 No abstract available.

6

Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine.

Stevens MF, Hickman JA, Langdon SP, Chubb D, Vickers L, Stone R, Baig G, Goddard C, Gibson NW, Slack JA, et al. Stevens MF, et al. Among authors: slack ja. Cancer Res. 1987 Nov 15;47(22):5846-52. Cancer Res. 1987. PMID: 3664486

7

Relationship between the pharmacokinetics and toxicity of mitozolomide.

Kerr DJ, Slack JA, Secrett P, Stevens MF, Blackledge GR, Bradley C, Kaye SB. Kerr DJ, et al. Among authors: slack ja. Cancer Chemother Pharmacol. 1990;25(5):352-4. doi: 10.1007/BF00686236. Cancer Chemother Pharmacol. 1990. PMID: 2306796

8

Predicting response to chemotherapy for patients with epithelial ovarian cancer using urinary polyamine excretion patterns.

Lawton FG, Griffin M, Slack JA, Blackledge G. Lawton FG, et al. Among authors: slack ja. Br J Cancer. 1990 Oct;62(4):692-4. doi: 10.1038/bjc.1990.359. Br J Cancer. 1990. PMID: 2223592 Free PMC article.

9

Antitumour imidazotetrazines, Part IX. The pharmacokinetics of mitozolomide in mice.

Goddard C, Slack JA, Stevens MF. Goddard C, et al. Among authors: slack ja. Br J Cancer. 1985 Jul;52(1):37-41. doi: 10.1038/bjc.1985.145. Br J Cancer. 1985. PMID: 4015951 Free PMC article.

10

Urinary polyamine excretion patterns in patients with epithelial ovarian cancer.

Lawton F, Griffin M, Slack J, Blackledge G. Lawton F, et al. Gynecol Obstet Invest. 1989;28(4):212-4. doi: 10.1159/000293581. Gynecol Obstet Invest. 1989. PMID: 2620864

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

36 results

Search Page

Filters